Filing Details

Accession Number:
0000899243-16-016130
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-16 16:37:14
Reporting Period:
2016-03-14
Filing Date:
2016-03-16
Accepted Time:
2016-03-16 16:37:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1105533 Argos Therapeutics Inc ARGS Pharmaceutical Preparations (2834) 562110007
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1543084 Sander Deventer Van C/O Forbion Capital Partners
Gooimeer 2-35
1411 Dc Naarden P7
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-03-14 881,745 $0.00 3,331,889 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Warrants (right to buy) Acquisiton 2016-03-14 661,309 $0.00 661,309 $5.35
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
661,309 2016-03-14 2021-03-14 No 4 P Indirect
Footnotes
  1. The reported securities are included within Units purchased by the Reporting Person for $5.44375 per Unit. Each Unit consists of one share of common stock and one warrant to purchase 0.75 shares of common stock.
  2. Represents reported securities held of record by ForArgos B.V.
  3. Forbion 1 Management B.V., the director of ForArgos, B.V., has voting and investment power over the reported securities held by ForArgos B.V., which are exercised through Forbion 1 Management B.V.'s investment committee, consisting of H. A. Slootweg, M. A. van Osch, G. J. Mulder and the Reporting Person. None of the members of the investment committee have individual voting and investment power with respect to such securities, and the members disclaim beneficial ownership of such securities except to the extent of their proportionate pecuniary interests therein.